Inventor
KUDUK SCOTT
US31 patents
⚠️ This page may combine multiple inventors who share the name “KUDUK SCOTT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVIRA THERAPEUTICS INC
20 patentsUS9181288B2Nov 10, 2015
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC103 citations98
US9505722B2Nov 29, 2016
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC24 citations94
US9339510B2May 17, 2016
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC25 citations94
US9169212B2Oct 27, 2015
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC28 citations94
US9550779B2Jan 24, 2017
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC10 citations92
US9527845B2Dec 27, 2016
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC11 citations92
US9518057B2Dec 13, 2016
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC10 citations92
US9890161B2Feb 13, 2018
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC3 citations84
US10556904B2Feb 11, 2020
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10544141B2Jan 28, 2020
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10538519B2Jan 21, 2020
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10189835B2Jan 29, 2019
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10093669B2Oct 9, 2018
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10077264B2Sep 18, 2018
Derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC2 citations73
US10987359B2Apr 27, 2021
Oxadiazepinone derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC0 citations52
US10975077B2Apr 13, 2021
Diazepinone derivatives and their use in the treatment of hepatitis B infections
NOVIRA THERAPEUTICS INC0 citations52
US10537580B2Jan 21, 2020
Azocane and azonane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC0 citations52
US9884831B2Feb 6, 2018
Azocane and azonane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC1 citations52
US9873671B2Jan 23, 2018
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC1 citations52
US10392349B2Aug 27, 2019
Azepane derivatives and methods of treating hepatitis B infections
NOVIRA THERAPEUTICS INC0 citations42
SLOAN KETTERING INST CANCER
5 patentsUS6204388B1Mar 20, 2001
Synthesis of epothilones, intermediates thereto and analogues thereof
SLOAN KETTERING INST CANCER143 citations98
US6660714B1Dec 9, 2003
α-O-linked glycoconjugates, methods of preparation and uses thereof
SLOAN KETTERING INST CANCER36 citations91
US7160856B2Jan 9, 2007
α-O-linked glycoconjugates, methods of preparation and uses thereof
SLOAN KETTERING INST CANCER17 citations82
US6603023B2Aug 5, 2003
Synthesis of epothilones, intermediates thereto and analogues thereof
SLOAN KETTERING INST CANCER12 citations73
US6965034B2Nov 15, 2005
Synthesis of epothilones, intermediates thereto and analogues thereof
SLOAN KETTERING INST CANCER3 citations62
YUHAN CORP
4 patentsUS11945798B2Apr 2, 2024
Substituted aminopyridine compounds as EGFR inhibitors
YUHAN CORP0 citations60
US12258328B2Mar 25, 2025
6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
YUHAN CORP0 citations59
US12258327B2Mar 25, 2025
5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
YUHAN CORP0 citations58
US11981658B2May 14, 2024
Substituted aminopyridine compounds as EGFR inhibitors
YUHAN CORP0 citations47